Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."

TSX:VRX - Post Discussion

View:
Post by coalbet on Mar 20, 2016 12:21pm

Oversold!

In trading on Tuesday, shares of Valeant Pharmaceuticals International Inc (NYSE: VRX) entered into oversold territory, hitting an RSI reading of 26.1, after changing hands as low as $37.24 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 63.1. A bullish investor could look at VRX’s 26.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of VRX shares:

Valeant Pharmaceuticals International Inc 1 Year Performance Chart

 

Looking at the chart above, VRX’s low point in its 52 week range is $37.24 per share, with $263.81 as the 52 week high point — that compares with a last trade of $38.74. Find out what 9 other oversold stocks you need to know about »

VRX makes up 2.22% of the Pharmaceutical ETF (AMEX: PPH)

Comment by FullReversal on Mar 20, 2016 1:33pm
Humm... coalbet,  you sound like a buddy of mine.... My buddy the trader says the exact same thing... Oversold! But your profile say 2014 and "novice"?  Humm.... Is that novice trading, investing or bullboarding??? Disclaimer.  Just watching VRX at the moment.  I work with a small team of investors that look at short attacks and profit from them.    I' ...more  
Comment by coalbet on Mar 20, 2016 4:58pm
I bought on friday and trading on the technicals of being oversold. I guess we will see in the coming week!  No i am not bullboarding just my perspective. Your team should have a look at TLT on the venture exchange ready for a breakout Going into Phase 1 human bladder treatment and oversold at the moment.
Comment by miscstuff on Mar 20, 2016 5:11pm
Don't mix me up with another poster. I don't have a team.
Comment by miscstuff on Mar 20, 2016 2:43pm
Coalbet: Just in case you think this is a buy signal, it isn't, as indicated by the trading in wed, thurs, fri. It "might be in oversold territory for a while. Consider buying as it comes out of oversold territory.
Comment by StevieCohen on Mar 20, 2016 7:32pm
Moron, it only becomes a buy when the RSI crosses back out of "oversold territory", otherwise it will just keep going down.  You guys are trying to catch a fuucking meteor.  At $15-20 it's maybe worth a trade, unless other info comes out clearly pointing to the equity being worthless.  Most of you morons don't understand a balance sheet and the bond market ...more  
Comment by d_trump on Mar 20, 2016 9:24pm
Good post Stevie.....this is not the time for technical analysis, not until their audit is signed off. And BTW Protrading has a dozen aliases - he is the former "shortattack" and now he is posting as Fullreversal.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities